Proffered Paper - Supportive and palliative care
LINK to STREAM (needs an ESMO registration)
LBA87 - A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)
The abstract concludes: Virtual pro-active toxicity management during CH did not lead to fewer EDH but was associated with less grade 3 toxicities and a smaller decline in QoL.
1809O - TRheuMa registry provides real world data on rheumatic immune-related adverse events
The abstract concludes: Prospective real world data from the TRheuMa-registry show that rheumatic irAEs mostly resemble classical RMDs with some distinct characteristics. Our clinical management strategy was effective and underlines our patient centred approach. Future research agenda includes long-term observation of irAE and specifically oncological outcomes.
1568O - Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis
The abstract concludes: This study is among the first to quantitatively summarize QOL in patients treated with ICIs. Findings suggest ICI recipients report overall stable QOL and better QOL than patients treated with non-ICI regimens. Results confirm that despite immune-related toxicities, ICIs are generally well-tolerated.
1810O - Impact of malnutrition according to the GLIM criteria in cancer patients admitted to hospital
The abstract concludes: The prevalence of malnutrition in cancer inpatients is high. Malnutrition measured by GLIM criteria and sarcopenia are associated with a high risk of NI. An adequate nutritional evaluation is essential for a timely implementation nutritional support, to avoid malnutrition, sarcopenia and decrease NI.
1504O - Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer
The abstract concludes: This is the first study demonstrating a significant association between CT-based diagnosis of sarcopenia and anthracycline-related cardiotoxicity. Routine CT scans may help clinicians identify high risk patients in whom closer follow-up or cardioprotective measures should be considered.